Clinical trials: Giant Cells Arteritis
Giant Cell Arteritis
Tocilizumab for Patients With Giant Cell Arteritis
Giant-cell arteritis (GCA) is an immune-mediated disease that mostly affects people older than 50 years of age. Glucocorticoid (GC) treatment dramatically alters the symptoms and course of GCA, reducing the likelihood of vascular…
- Trial name
- NCT01450137
- Testing
- Tocilizumab + Glucocorticoids (GCs)
- Where
- Switzerland
- Volunteers
- 30 people
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Giant Cell Arteritis
HECTHOR: Humira to Spare Steroids in Giant Cell Arteritis
Hypothesis: In giant cell arteritis (GCA), a short initial treatment with anti-TNF may allow a faster decrease of steroids dosage and therefore avoid some of the adverse events of steroids.
- Trial name
- NCT00305539
- Testing
- adalimumab
- Where
- France
- Volunteers
- 69 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Giant Cell Arteritis
A Clinical Trial to Investigate 18F-AzaFol in the Diagnosis of Large Vessel Vasculitis
The goal of this open-label clinical trial is to evaluate the efficacy of AzaFol-PET/CT in the diagnosis of GCA (giant cell arteritis), to compare AzaFol- with 2-[18F]FDG-PET/CT, and to assess the safety and tolerability of…
- Trial name
- CRAFT (NCT06335888)
- Testing
- AzaFol, FDG
- Where
- Switzerland
- Volunteers
- 70 people
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Giant Cell Arteritis (GCA)
A Study to Evaluate the Safety and Efficacy of Upadacitinib in Participants With Giant Cell Arteritis
This study consists of two periods. The objective of Period 1 is to evaluate the efficacy of upadacitinib in combination with a 26-week corticosteroid (CS) taper regimen compared to placebo in combination with a 52-week CS taper…
- Trial name
- SELECT-GCA (NCT03725202)
- Testing
- Upadacitinib, Corticosteroid (CS)
- Where
- 172 sites in United States, Australia and 22 more
- Volunteers
- 429 people
- Sponsor
- AbbVie
Vasculitis, Systemic Vasculitis
Impact of Vasculitis on Employment and Income
The purpose of this study is to learn about the impact of vasculitis on employment and income in patients with different systemic vasculitides.
- Conditions
- Vasculitis, Systemic Vasculitis, Behcet's Disease, CNS Vasculitis
- Trial name
- NCT02476292
- Testing
- online questionnaire
- Where
- United States
- Volunteers
- 426 people
- Sponsor
- University of South Florida
Giant Cell Arteritis
Efficacy and Safety Study of Sirukumab in Patients With Giant Cell Arteritis
Sirukumab is a fully human anti-interleukin-6 (IL-6) immunoglobulin G1-kappa with a high affinity and specificity for binding to the human IL-6 molecule that may have therapeutic benefit in the treatment of giant cell arteritis…
- Trial name
- NCT02531633
- Testing
- Sirukumab, Prednisone
- Where
- 63 sites in United States, Australia and 11 more
- Volunteers
- 161 people
- Sponsor
- GlaxoSmithKline
Patients Relapsing Refractory Giant Cell Arteritis
Ustekinumab for the Treatment of Relapse of Refractory Giant Cell Arteritis
Giant cell arteritis (GCA) is the most common form of vasculitis after age 50. It is a vasculitis affecting the large vessels, in particular the aorta and its collateral vessels, especially those in the external carotid area.
- Trial name
- ULTRA (NCT03711448)
- Testing
- prednisone treatment, prednisone and ustekinumab treatment, questionnaires
- Where
- France
- Volunteers
- 38 people
- Sponsor
- Centre Hospitalier Universitaire Dijon
Ankylosing Spondylitis (AS), Psoriatic Arthritis (PsA)
A Registry Study Assessing PRO, Dosing Patterns, and Safety of Vunakizumab in Patients With General Rheumatic Diseases.
Ankylosing spondylitis, radiographically negative axial spondyloarthritis, psoriatic arthritis, polymyalgia rheumatica, Takayasu arteritis, giant cell arteritis, non-ocular Behcet's disease, and enthesitis-related arthritis are…
- Conditions
- Ankylosing Spondylitis (AS), Psoriatic Arthritis (PsA), Nr-axSpA, Polymyalgia Rheumatica (PMR)
- Trial name
- V-MIRACLE (NCT06766552)
- Where
- China
- Volunteers
- 10,000 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Aortitis, Giant Cell Arteritis (GCA)
TocILizumab in aorTitis in GCA (TILT)
This is a french multicenter observational study assessing safety and efficacy of biosimilar of Tocilizumab in Giant Cell Arteritis (GCA) with active aortitis, including 14 reference centers from the Groupe d'Etude Français des…
- Trial name
- TILT (NCT06271018)
- Where
- France
- Volunteers
- 80 people
- Sponsor
- Groupe français d'étude des Maladies Inflammatoires de loeil
Giant Cell Arteritis
MEthotrexate Versus TOcilizumab for Treatment of GIant Cell Arteritis: a Multicenter, Randomized, Controlled Trial
Giant-cell arteritis (GCA) is the most frequent vasculitis after 50 years. It is characterized by a granulomatous inflammation of the wall of large vessels, involving especially the aorta and extra-cranial branches of the…
- Trial name
- METOGiA (NCT03892785)
- Testing
- Prednisone treatment, Tocilizumab treatment, Methotrexate treatment
- Where
- France
- Volunteers
- 230 people
- Sponsor
- Centre Hospitalier Universitaire Dijon
Rheumatoid Arthritis, Idiopathic Juvenile Arthritis
Pharmacogenetic Studies on Anti-IL-6 Receptor Monoclonal Antibodies on the Treatment of Rheumatic Diseases
Tocilizumab and Sarilumab are first-line biological disease-modifying anti-rheumatic drug (bDMARD) which inhibits Interleukin 6 (IL-6) pathway through blockade of its receptor on the treatment of Rheumatoid Arthritis and other…
- Conditions
- Rheumatoid Arthritis, Idiopathic Juvenile Arthritis, Giant Cell Arteritis, Still Disease
- Trial name
- NCT05045001
- Where
- Spain
- Volunteers
- 140 people
- Sponsor
- Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Temporal Arteritis, Duplex of Temporal Artery
Sensitivity and Specificity of Color Doppler Directed Temporal Artery Biopsy as Compared to Standard Random Biopsy in the Diagnosis of Temporal Arteritis
Introduction Temporal arteritis (TA) is the most common primary vasculitis in the adult population. TA is a systemic multi-organ disease but primarily involves the cranial arteries, especially the temporal artery.
- Conditions
- Temporal Arteritis, Duplex of Temporal Artery, Biopsy of Temporal Artery
- Trial name
- NCT00361192
- Testing
- biopsy of temporal artery
- Where
- Israel
- Sponsor
- Shaare Zedek Medical Center
Polymyalgia Rheumatica, Giant Cell Arteritis
Improved Diagnostics and Monitoring of Polymyalgia Rheumatica
Background: Polymyalgia rheumatica (PMR) is characterised by pain of the proximal muscles, general symptoms, and raised inflammatory markers. Treatment with prednisolone has several adverse effects.
- Conditions
- Polymyalgia Rheumatica, Giant Cell Arteritis, Adrenal Insufficiency
- Trial name
- NCT04519580
- Testing
- PET/CT
- Where
- 3 sites in Denmark
- Volunteers
- 98 people
- Sponsor
- Kresten Krarup Keller
Giant Cell Arteritis
Assessment of Giant Cell Arteritis Medical Practices in France
The purpose of this study is to describe medical practices in patients with GCA in terms of patient journey, diagnostic methods and specific GCA treatments since diagnosis.
- Trial name
- ARTEMIS (NCT03658889)
- Where
- France
- Volunteers
- 306 people
- Sponsor
- Chugai Pharma France
Giant Cell Arteritis
Investigation of the Influence of the Human Microbiome on Giant Cell Arteritis
The longitudinal observational study aims to assess the impact of the microbiome especially the gut-microbiome in the emergence and course of giant cell arteritis (abbr. GCA) patients.
- Trial name
- GCA-Biom (NCT06279065)
- Testing
- Analysis of blood and microbiome samples (stool, oral lavage)
- Where
- 2 sites in Germany
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- University of Bonn
Giant Cell Arteritis
Phase II Randomized Study of Glucocorticoids With or Without Methotrexate for Treatment of Giant Cell Arteritis
OBJECTIVES: I. Compare the long term outcomes in patients with giant cell arteritis after glucocorticoid treatment with or without methotrexate. II.
- Trial name
- NCT00004686
- Testing
- methotrexate, prednisone
- Volunteers
- 300 people
- Sponsor
- The Cleveland Clinic
Vasculitis, Systemic Vasculitis
Journey of Patients With Vasculitis From First Symptom to Diagnosis
This study seeks to understand the journey that patients eventually are diagnosed with vasculitis experience in the period prior to their formal diagnosis by a healthcare provider.
- Conditions
- Vasculitis, Systemic Vasculitis, Behcet's Disease, CNS Vasculitis
- Trial name
- NCT03410290
- Testing
- Online Questionnaire
- Where
- United States
- Volunteers
- 456 people
- Sponsor
- University of Pennsylvania
Giant Cell Arteritis (GCA)
Tocilizumab Discontinuation Versus Dose Reduction for Patients With Well-Controlled Giant Cell Arteritis
This is a multi-center, randomized, open label study that will assess the efficacy and safety of ACTEMRA(R) or one of its FDA-approved biosimilars Tocilizumab (TCZ) maintenance versus withdrawal in Giant cell arteritis (GCA)…
- Trial name
- NCT07108387
- Testing
- Tocilizumab, Discontinue Tocilizumab
- Where
- 7 sites in United States
- Volunteers
- 78 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Giant Cell Arteritis (GCA)
Treatment for Giant Cell Arteritis With Tocilizumab and 8 as Compared to 26 Weeks of Prednisone
The GISCO study plans to determine whether 8-week therapy is just as effective as 26-week cortisone therapy for treating giant cell arteritis with tocilizumab, while using less cortisone.
- Trial name
- GISCO (NCT06833411)
- Testing
- Prednisone
- Where
- Switzerland
- Volunteers
- 178 people
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Inflammatory Rheumatism, Polymyalgia Rheumatica
PRediction Of DIverse Glucocorticoids toxIcity OUtcomeS
To date, there is no available tool that allows, at individual level, determination of the probability to develop clinically relevant complications of prolonged glucocorticoid therapy.
- Conditions
- Inflammatory Rheumatism, Polymyalgia Rheumatica, Giant Cell Arteritis, Idiopathic Inflammatory Myopathies
- Trial name
- PRODIGIOUS (NCT04664465)
- Where
- 12 sites in France
- Volunteers
- 300 people
- Sponsor
- University Hospital, Brest